Skip to main content
Transgene logo

Transgene — Investor Relations & Filings

Ticker · TNG ISIN · FR0005175080 LEI · 969500PDJW8N0FSGGK69 PA Professional, scientific and technical activities
Open in API
Filings indexed 796 across all filing types
Latest filing 2021-01-06 Transaction in Own Shar…
Country FR France
Listing PA TNG

About Transgene

https://www.transgene.fr/en/

Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.

Recent filings

Filing Released Lang Actions
Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract
Transaction in Own Shares Classification · 1% confidence The document is a short announcement dated January 6, 2021, detailing the resources (shares and cash) allocated under a 'Liquidity Contract' with a financial institution (Natixis Oddo BHF SCA) as of December 31, 2020. This type of filing relates to market making activities, which often involves the company managing its own shares in the market. This aligns most closely with 'Transaction in Own Shares' (POS), as liquidity contracts are mechanisms for managing share supply/demand, which is a form of share transaction activity. It is not a full financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS). Given the context of managing share availability via a contract, POS is the most specific fit.
2021-01-06 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated December 21, 2020, announcing that Transgene and BioInvent have received regulatory approval in Belgium for a Clinical Trial Application (CTA) to initiate a Phase 1/2a study for their oncolytic virus BT-001. This is a specific announcement regarding clinical development progress and regulatory milestones, not a comprehensive annual report (10-K), a quarterly report (IR), or a general earnings release (ER). It is a specific corporate update related to drug development and regulatory progress. Since there is no specific code for 'Clinical Trial Application Approval Announcement' or 'Biotech Development Update', and it is not a standard financial filing like 10-K or MRQ, it falls best under the general 'Regulatory Filings' (RNS) category as a significant, non-standard regulatory announcement, or potentially 'LTR' if viewed as a legal/regulatory step, but RNS is the most appropriate general regulatory announcement fallback when specific codes like ER, IR, or 10-K do not apply. Given the context of a press release detailing a regulatory approval for a clinical trial, RNS (Regulatory Filings) is the best fit as a general regulatory announcement.
2020-12-21 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated December 21, 2020, jointly issued by Transgene and BioInvent. The core content announces that they have received authorization from the Belgian health authority to commence a Phase 1/2a clinical trial for their oncolytic virus, BT-001. This announcement details the trial design (Phase 1/2a, dose escalation, combination therapy with pembrolizumab) and provides background on the drug and the collaboration. This type of announcement, detailing progress in clinical development and regulatory milestones, is characteristic of an Earnings Release (ER) if it were summarizing period results, or more specifically, a general corporate update. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change (MANG), it falls under general corporate news. Given the options, it is a significant corporate announcement regarding product development progress. While it contains elements of an Earnings Release (ER) by announcing progress, it is primarily a specific operational update. However, in the context of financial filings, announcements of clinical trial initiations are often categorized broadly. Since it is not a formal regulatory filing like a 10-K or a specific financial report, and it is not a simple 'report publication announcement' (RPA), the most fitting category for a major operational/development update that isn't a formal financial report is often the general 'Regulatory Filings' (RNS) if no better fit exists, or sometimes 'Earnings Release' (ER) if it's part of a quarterly update cycle, though this document is focused purely on the trial initiation. Given the specific nature of announcing a clinical trial start, and lacking a dedicated 'Clinical Trial Update' code, 'Regulatory Filings' (RNS) serves as the best general category for significant, non-financial, non-management corporate news that must be disclosed, or 'ER' if we interpret it as a major operational highlight often bundled with earnings. Since it is a standalone press release detailing a major operational milestone (clinical trial start), and not a formal financial report, RNS is the most appropriate fallback for significant, non-standard disclosures.
2020-12-21 French
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is a short press release dated December 17, 2020, titled "Transgene présente son calendrier de communication financière pour 2021" (Transgene presents its 2021 financial communication calendar). It explicitly lists the dates for future events such as the Annual Results, Quarterly Results, and the General Shareholders' Meeting. Since the document's primary function is to announce *when* future reports and meetings will occur, rather than being the report itself (like a 10-K or ER), it fits the definition of a Report Publication Announcement (RPA). The document length (2712 chars) is also short, supporting the RPA classification over the full report classification.
2020-12-17 French
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is titled "Transgene Announces Financial Calendar for 2021" and explicitly lists the dates for future financial results (2020 Fiscal Year Results, Q1 2021, H1 2021, Q3 2021) and the Annual Shareholders' Meeting. This document is not the financial report itself (like 10-K or IR), nor is it a transcript or a detailed presentation. It is an announcement about the schedule for future corporate events and report publications. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports.
2020-12-17 English
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 1% confidence The document is a short announcement from Transgene dated December 16, 2020, stating its participation in several upcoming investor conferences in January 2021 (LifeSci Advisors Corporate Access Event, Oddo BHF Digital Forum, Biomed Event). It lists the events and dates but does not contain detailed financial results, management changes, or regulatory filings. Since the core purpose is to inform investors about upcoming meetings where the company will present, this aligns best with an Investor Presentation (IP) announcement or general investor relations activity. Given the options, 'Investor Presentation' (IP) is the most fitting category as these meetings are where presentations are typically given, even if the document itself is just the schedule. It is not a formal report (10-K, IR) nor a specific transaction notice (DIV, DIRS). It is an announcement about future investor engagement.
2020-12-16 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.